Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0359)
| Name |
Kayadiol
|
||||
|---|---|---|---|---|---|
| Synonyms |
KAYADIOL; CHEMBL1277840; BDBM50483054
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C20H34O2
|
||||
| IUPAC Name |
(Z)-5-[(1S,4aR,5R,8aR)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-en-1-ol
|
||||
| Canonical SMILES |
CC(=CCO)CCC1C(=C)CCC2C1(CCCC2(C)CO)C
|
||||
| InChI |
InChI=1S/C20H34O2/c1-15(10-13-21)6-8-17-16(2)7-9-18-19(3,14-22)11-5-12-20(17,18)4/h10,17-18,21-22H,2,5-9,11-14H2,1,3-4H3/b15-10-/t17-,18-,19-,20+/m0/s1
|
||||
| InChIKey |
MJHWZTRFACWHTA-COPBVACWSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | T-cell lymphoma | ICD-11: 2B01 | ||
| Responsed Regulator | Cellular tumor antigen p53 (TP53) | Driver | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | YT cells | Natural killer cell lymphoblastic leukemia | Homo sapiens | CVCL_1797 |
| hPBLs (Human peripheral blood lymphocytes) | ||||
| Response regulation | Kayadiol decreased the expression of SLC7A11 and GPX4, the negative regulatory proteins for ferroptosis. And p53 was the key mediator of kayadiol-induced ferroptosis by SLC7A11/GPX4 axis through p53 knockout experiments. Kayadiol can serve as an effective alternative in the treatment of NK/T cell lymphoma. | |||